Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter

Revicki, Dennis A.; Moyle, Graeme; Stellbrink, Hans‐Jürgen; Barker, Chris

doi:10.1097/00002030-199905070-00016

Cited by 57 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adult studies suggest that PI combination therapy can improve, maintain, or attenuate declines in QOL over time. [30][31][32][33] Call et al 34 noted that lower viral loads and higher CD4 ϩ cell counts predicted better QOL in some domains, including general health and physical and role functioning, but did not predict mental health scores. In the HIV Cost and Services Utilization Study, adults' physical functioning depended on symptom status or AIDS diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Protease Inhibitor Combination Therapy, Severity of Illness, and Quality of Life Among Children With Perinatally Acquired HIV-1 Infection

Storm¹,

Boland²,

Gortmaker

et al. 2005

Pediatrics

View full text Add to dashboard Cite

ABSTRACT.Objectives. This study examines quality of life (QOL) among school-aged children with perinatally acquired HIV infection and compares QOL outcomes between treatment groups that differ according to the use of protease inhibitor (PI) combination therapy (PI therapy). To gain insights into how PI therapy might influence QOL, associations between severity of illness and QOL were also investigated.Methods. Cross-sectional data for 940 children, 5 to 18 years of age, who were enrolled in Pediatric AIDS Clinical Trials Group Late Outcomes Protocol 219 were used to examine domains of caregiver-reported QOL, as assessed with the General Health Assessment for Children, during 1999. The General Health Assessment for Children is an age-specific, modular, QOL assessment that was developed for the study with previously validated measures. QOL differences between treatment groups were estimated with linear and logistic regressions that controlled for sociodemographic characteristics (age, gender, race/ethnicity, maternal/caregiver education, and respondent) and severity-of-illness indicators related to receipt of PI therapy (AIDS status, log 10 CD4 ؉ cell counts, and height-for-age z scores).Results. The mean age of participants was 9.7 years. Most children were non-Hispanic black (54%) or Hispanic (31%), and 49% of the participants were female. At the 1999 study visit, ϳ14% of children had severe immune suppression (<15% CD4 ؉ cells), whereas 62% of children had >25% CD4 ؉ cells, ie, no immune suppression. Participants did exhibit some lag in growth, with mean height and weight z scores of ؊0.70 and ؊0.20, respectively. Twenty-eight percent of the children were reported to have met criteria for AIDS at study entry (1993)(1994)(1995)(1996)(1997)(1998)(1999). When treatment groups were compared, children receiving PI therapy (72%) were older, had lower CD4 ؉ cell percentages, and had lower height and weight z scores than did those receiving non-PI therapies. They were also more likely to have met criteria for AIDS at study entry. The most commonly used PIs were ritonavir (46%) and nelfinavir (63%). Health perceptions ratings for most children were at the upper end of the scale, whereas ratings for 25% of the children ranged over the lower 70% of scale scores. Almost one half of the children had at least some limitations in physical functioning, with more frequent limitations in energydemanding activities (46%) than in basic activities of daily living (32%). The Behavior Problems Index was used to assess psychologic functioning. The mean total Behavior Problems Index score (9.34) and the proportion of children with extreme scores (23%) were consistent with values reported for chronically ill children and those at social and economic risk. One or more limitations in social/school functioning were reported for 58% of children. More than one third of the children (38%) experienced >1 physical symptoms that were at least moderately distressing. Health perceptions, physical functioning, psychologic functioning, social/school...

show abstract

Section: Discussionmentioning

confidence: 99%

Protease Inhibitor Combination Therapy, Severity of Illness, and Quality of Life Among Children With Perinatally Acquired HIV-1 Infection

Storm¹,

Boland²,

Gortmaker

et al. 2005

Pediatrics

View full text Add to dashboard Cite

show abstract

“…Since 1997, it has been used in clinical trials [8] and cross-sectional and cohort studies (i.e. from PROME-THEUS [11] and PISCES study groups [12] to other investigators of HRQoL in HIV [2,13], and it has numerous validated translations [14][15][16][17][18][19]). This questionnaire shares the same common pool of items with the SF-36 of the Medical Outcomes Study, but some additional domains of HRQoL measures were added to produce a 30-item form of the MOS-HIV [7].…”

Section: Instrumentmentioning

confidence: 99%

Reliability and validity of the Greek translation of the MOS-HIV health survey in HIV-infected individuals

Stasinopoulou¹,

Tzavara

Dimitrakaki

et al. 2010

Qual Life Res

View full text Add to dashboard Cite

show abstract

“…The susceptibility of the immune system to opportunistic illness, the presence of symptoms, and the chronic as well as acute episodic nature of disease progression can all have a significant negative impact on quality of life [3,4]. Although multiple drug therapies curtail disease progression, they are often associated with negative side-effects that may impact HRQOL [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Nature and correlates of SF-12 physical and mental quality of life components among low-income HIV adults using an HIV service center

Viswanathan

Anderson²,

Thomas

2005

Qual Life Res

View full text Add to dashboard Cite

show abstract

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter

Abstract: Patients on triple combination therapy maintained their quality of life over 48 weeks compared with significant decreases in the quality of life for ddC/ZDV combination therapy.

Cited by 57 publications

References 24 publications

Protease Inhibitor Combination Therapy, Severity of Illness, and Quality of Life Among Children With Perinatally Acquired HIV-1 Infection

Protease Inhibitor Combination Therapy, Severity of Illness, and Quality of Life Among Children With Perinatally Acquired HIV-1 Infection

Reliability and validity of the Greek translation of the MOS-HIV health survey in HIV-infected individuals

Nature and correlates of SF-12 physical and mental quality of life components among low-income HIV adults using an HIV service center

Contact Info

Product

Resources

About